Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation

Exercise Therapy for Patients Awaiting Allogeneic Hematological Stem Cell Transplantation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02273024

Enrollment

Registered

2014-10-23

Start date

2014-10-31

Completion date

2019-08-31

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogeneic Stem Cell Transplantation

Keywords

Exercise, Quality of Life, Fatigue, Symptoms, Prehabilitation, Aerobic Capacity

Brief summary

The investigators hypothesize that inactivity during the search for a donor may exacerbate current deconditioned states; subsequently, influencing risk factors for post-transplant complications that hinder the recovery phase. This study is designed to investigate if exercise therapy administered prior to allogeneic hematologic stem cell transplantation (HSCT) can influence physical and psychological side-effects associated with HSCT. Approximately 6-weeks prior to HSCT, individuals will be randomized into either an exercise group or usual care group and followed until one year after HSCT.

Interventions

BEHAVIORALExercise

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

17 Years to No maximum

Healthy volunteers

Inclusion criteria

* Medical indication: allogeneic stem cell transplantation at Princess Margaret Hospital * must be ambulatory without need for human assistance at time of recruitment * medically cleared to exercise by the transplant physician * demonstrates willingness to attend supervised sessions * sufficient in English to ensure safety of understanding prescribed exercise guidelines, or has access to an adequate non-familial interpreter

Exclusion criteria

* another active malignancy * less than 4 weeks till the scheduled HSCT * refusal to be randomized * does not have the approval of their transplant physician * severe or unstable neurological, cardiorespiratory, musculoskeletal disease or mental illness

Design outcomes

Primary

Measure	Time frame	Description
Change in Physical Function	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	Cardiopulmonary Capacity (VO2peak)

Secondary

Measure	Time frame	Description
Change in Quality of Life	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	European Organization for Research and Treatment of Cancer (EORTC) core 30-item questionnaire (QLQ-30)
Change in Symptoms	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	Memorial Symptom Assessment Scale (MSAS)
Change in Anxiety	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	The Generalized Anxiety Disorder (GAD7)
Change in Depression	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	The Patient Health Questionnaire (PHQ-9), will be used as a clinically relevant measure to evaluate depression
Change in Treatment Side-effects	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	Hospitalization (days till discharge and readmission rates), bone marrow engraftment (days), graft versus host disease incidence (acute & chronic), severity of diarrhea/ vomiting/ nausea, infections, steroid use, blood counts
Change in Strength	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	upper body: grip strength; lower body: chair-stand test
Change in Six-minute walk test	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	—
Change in Fatigue	Baseline, 1 week pre HSCT, T100, 1yr post HSCT	Multidimensional Fatigue Inventory

Other

Measure	Time frame	Description
Adherence to exercise sessions	One year	Feasibility of an exercise intervention prior to HSCT till T100

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026